Lilly Bets $8B on Weight Loss Future

On The Pen GLP-1 News

[SPEAKER_A] Eli Lilly just purchased a sleep company for almost $8 billion, and I think most people are completely misunderstanding just why they did that, because I believe that the future of obesity medicine is going to start to be less and less about appetite suppression and more about energy expenditure. We're going to get into all that on today's episode of The Weekly Dose Podcast. Welcome back. Welcome to the On the Pen podcast with your host, Dave Knapp. Welcome back to the Weekly Dose podcast. I'm your host, Dave Knapp, man on the Munjaro. That's why I'm here. You are on the pin. Wegovy, Saxenda, Victoza, Trulicity, Manjaro, Zepbound, Compound. That pin. And each and every week, we try to bring you patient-centric obesity medicine news that empowers you to have better conversations with your doctor. And today's topic, honestly, I think could end up being one of the biggest future stories in obesity medicine because for the last few years, obesity medicine has largely revolved around one major concept and that is Appetite suppression, reducing caloric intake. And GLP-1s suppress appetite. GIP suppresses appetite, improves satiety. Of course, they're doing a lot of other metabolic things too, but primarily they're reducing caloric intake. And even amylin, the future amylin products that are coming out like iloralintide and cagrilatide, they suppress appetite. Food noise reduction has become one of the defining features of the obesity class of medications and one of the defining experiences of this entire generation of obesity medications. And for millions of people, this drug has changed their lives. It's given them complete freedom because for the first time they realized, my goodness, I don't think this has been about my own self-discipline all along. This has been about biology driving hunger.

Lilly Bets $8B on Weight Loss Future

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Lilly Bets $8B on Weight Loss Future

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.